Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.37 |
| ▸ | RXRB | P28702 | 16/20 | 0.37 |
| ▸ | RXRG | P48443 | 14/20 | 0.37 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 3/20 | 0.32 |
| ▸ | RARG | P13631 | 3/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927542 | 0.92 | — | — | |
| SCHEMBL22934084 | 0.90 | RXRA (0.39) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL22936149 | 0.87 | RXRA (0.43) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL22938028 | 0.87 | RXRA (0.43) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL23445205 | 0.84 | RXRA (0.36) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL23442772 | 0.82 | RXRA (0.39) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL24084621 | 0.82 | RXRA (0.34) | RXRARXRBRXRGCYP26B1 | |
| SCHEMBL23446678 | 0.81 | RXRA (0.38) | RXRARXRBRXRG | |
| SCHEMBL22934181 | 0.81 | RXRA (0.41) | RXRARXRBRXRGCYP26B1RARB | |
| SCHEMBL23447252 | 0.80 | RXRA (0.38) | RXRARXRBRXRGCYP26B1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559467-B2 | Organic light emitting device | LG CHEM, LTD. (KR) | 2026-02-24 | — | — | US | disclosed |
| US-12497415-B2 | Polycyclic compound and organic light-emitting element comprising same | LG CHEM, LTD. (KR) | 2025-12-16 | — | — | US | disclosed |
| US-20230077439-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| US-20230084250-A1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEM, LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| US-20230002420-A1 | ORGANIC LIGHT-EMITTING ELEMENT | LG CHEM, LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20220399501-A1 | ORGANIC LIGHT-EMITTING ELEMENT | LG CHEM, LTD. (KR) | 2022-12-15 | — | — | US | disclosed |
| EP-3901158-A2 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG Chem, Ltd. (KR) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002420-A1 | ORGANIC LIGHT-EMITTING ELEMENT | CYBA, CRY1, CYP1A1 | RXRA 1129/4885RXRB 1315/4885RXRG 1292/4885 |
| US-20220399501-A1 | ORGANIC LIGHT-EMITTING ELEMENT | CYP1A1, AHR, CYP1B1 | RXRA 1281/4885RXRB 1573/4885RXRG 1398/4885 |
| US-20230077439-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CYBA, CRY2, CRY1 | RXRA 1813/4885RXRB 1739/4885RXRG 1509/4885 |
| US-12497415-B2 | Polycyclic compound and organic light-emitting element comprising same | CYBA, CRY2, CRY1 | RXRA 1813/4885RXRB 1739/4885RXRG 1509/4885 |
| US-20230084250-A1 | ORGANIC LIGHT EMITTING DEVICE | CRY1, CRY2, PER2 | RXRA 2086/4885RXRB 2472/4885RXRG 2376/4885 |
| US-12559467-B2 | Organic light emitting device | CRY1, RPS24, ARL1 | RXRA 913/4885RXRB 919/4885RXRG 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.